Arcturus Therapeutics Holdings, Inc. (ARCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.82+1.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce operating losses toward breakeven: metric not reported.
Arcturus has a strategic partnership with Thermo Fisher to boost its cystic fibrosis drug. Management aims to keep cash running past Q2 2028. They are working to reduce operating losses which improved slightly from -$33.4M to -$28.9M. This partnership and cash runway give hope for recovery.
Revenue is falling sharply, down from $29.4M to $2.1M in one year. The company is still losing money and analysts expect revenue to shrink nearly 29% next year. Operating losses remain large and cash burn is a risk. The turnaround may stall or fail.
The market expects about 29% revenue decline and a continued loss-making profile. Our fair value near $27 suggests the price reflects a tough outlook. We see risk if losses deepen or revenue falls faster than expected.
Breaks if: Cash runway falls below Q2 2028
Continue disciplined capital allocation to sustain cash runway through the second quarter of 2028 to support clinical and regulatory milestones.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on advancing its clinical programs, which could drive future growth.
The market appears to have priced in a stretched valuation compared to peers, reflecting a premium. There is a modest expectations gap, indicating that investors may be anticipating some improvement in performance.
Management is making progress on key clinical programs, but recent financial performance has been weak. The company is focused on maintaining its cash runway while advancing its drug development efforts.
The long-term thesis hinges on the success of clinical trials and the ability to maintain cash reserves. Additionally, broader sector performance and economic conditions will influence ARCT's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Management consistently emphasizes maintaining a cash runway beyond Q2 2028. Cash and cash equivalents declined from $213.4 million at 2026-Q1 to $191.5 million at 2026-Q2, reflecting ongoing clinical development spend. The trajectory shows disciplined capital allocation sustaining runway as promised.
“We continue to have a cash runway extending beyond the second quarter of 2028.”
“We continue to have a cash runway extending beyond the second quarter of 2028.”
“Arcturus has extended its cash runway into the second quarter of 2028.”
Breaks if: Operating loss worsens beyond -$28.9M
Breaks if: Revenue falls below $2M or declines further
Breaks if: Partnership fails to deliver expected benefits or dissolves
In the next 1 to 3 years, ARCT's performance will depend on its clinical advancements and external market factors. Not investment advice.